Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about

< Previous 1 2 3 4 5 6 Next >
Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL) today announced the closing of the previously announced transaction with Annapurna Therapeutics. The combined company has been renamed Adverum... 
From GlobeNewswire News Releases
Avalanche Biotechnologies’ Stockholders Vote in Favor of Annapurna Transaction
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL) today announced that its stockholders, at its annual meeting held today, approved the issuance of shares of the Company’s common stock to the shareholders... 
From GlobeNewswire News Releases
U.S. RESEARCH ROUNDUP-Weatherford, General Motors, Endo International
May 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Total System Services, Ubiquiti Networks and Advance Auto Parts, on... 
Tags companyNews
From Reuters: Company News
Biggest Movers in Manufacturing Stocks Now – ROCK CLLS FOE AVXS
 
Tags NYSE:SPXC NASDAQ:CLLS Hot Stocks
From InvestorPlace
Implied IUSG Analyst Target Price: $91
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BRIEF-Avalanche Biotechnologies Q1 loss per share $0.57
* Avalanche Biotechnologies, Inc. Reports first quarter 2016 financial results 
Tags companyNews
From Reuters: Company News
Avalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment... 
From GlobeNewswire News Releases
Commit To Buy Avalanche Biotechnologies At $5, Earn 24.1% Annualized Using Options
Investors eyeing a purchase of Avalanche Biotechnologies, Inc. (AAVL) stock, but cautious about paying the going market price of $5.51/share, might benefit from considering selling puts among the... 
Tags Stocks
From Market News Video
18 Biotechnology Stocks to Sell Now
 
Tags NASDAQ:EPZM Stocks to Sell NASDAQ:APPY
From InvestorPlace
Avalanche Biotechnologies to Present at Upcoming Scientific Meetings
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment... 
From GlobeNewswire News Releases
I'm watching these 5 Biotech Stocks
Tags AAVL CMRX VRX
From AC Investor Blog
Look Under The Hood: IBB Has 56% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Science Center’s Global Soft Landing Program Grows with Addition of Companies from France and U.K.
Tags Science: General Business: Sales Business: Personnel
From PRWeb
Avalanche Posts Wider-than-Expected 4Q Loss
Being a development-stage company, Avalanche does not have any approved product in its portfolio yet. In this scenario, investors are expected to keep an eye on pipeline development at the company,... 
Tags Stocks / Equities Healthcare
From Blogs - TalkMarkets
Avalanche Biotechnologies Reports Fourth Quarter and Fiscal 2015 Financial Results
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a gene therapy company committed to discovering and developing novel medicines for patients suffering from chronic or debilitating disease, today reported... 
From GlobeNewswire News Releases
Avalanche Biotechnologies to Present at Upcoming Investor Conferences
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a gene therapy company committed to discovering and developing novel medicines for patients with chronic or debilitating disease, today announced that... 
From GlobeNewswire News Releases
How The Parts Add Up: UWM Headed For $78
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Hottest Manufacturing Stocks Now – TWI BRCD XENE TTPH
 
Tags NASDAQ:AERI NASDAQ:BRCD NASDAQ:AAVL
From InvestorPlace
Dozens of biotech companies are ‘free’ for investors’ taking
They’re trading at less than net cash, making them bargains — and also risky, so buyer beware, says Michael Brush. 
Tags Health/Care PRTA Personal Finance
From MarketWatch
Biggest Movers in Manufacturing Stocks Now – COLL EDGE ASMB HPJ
 
Tags NASDAQ:ADAP NASDAQ:NYMX NYSE:WAB
From InvestorPlace
40 Biotechnology Stocks to Sell Now
 
Tags NASDAQ:HTBX NASDAQ:FATE NASDAQ:GLYC
From InvestorPlace
Avalanche Biotechnologies Inc (NASDAQ:AAVL) Shareholder Alert: Lawsuit in Connection with Jan. 2015 Stock Offering Filed
San Diego, CA -- (SBWIRE) -- 02/02/2016 -- A shareholder in Avalanche Biotechnologies Inc's follow-on public stock offering completed on January 13, 2015 filed a lawsuit over alleged violations of... 
From SBWire - Latest Press Releases
Benzinga's M&A Chatter for Monday February 1, 2015
The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday February 1, 2015: Abbott to Acquire Alere ... 
Tags Rumors SVA CAMP
From Benzinga
Avalance Biotechnologies Tumbles 14% Following Acquisition Announcement
Shares of Avalanche Biotechnologies Inc (NASDAQ: AAVL) plunged to a new 52-week low of $5.07 on Monday and was trading lower by more ... 
Tags Avalanche Biotechnologies Biotech Movers
From Benzinga
Stocks Hitting 52-Week Lows
Ability Inc (NASDAQ: ABIL) shares fell 7.60 percent to touch a new 52-week low of $7.90. Ability shares have declined 13.14 percent ... 
Tags ABIL AAVL 52 Week Lows
From Benzinga
Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger
Combined Scientific, Financial and Human Resources Will Support Robust Gene Therapy Pipeline Companies to Host Conference Call Today at 8:00 a.m. ET/ 5:00 a.m. PT 
From GlobeNewswire News Releases
Commit To Buy Avalanche Biotechnologies At $5, Earn 20.3% Annualized Using Options
Investors eyeing a purchase of Avalanche Biotechnologies, Inc. (AAVL) shares, but cautious about paying the going market price of $6.20/share, might benefit from considering selling puts among the... 
Tags Stocks
From Market News Video
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Avalanche Biotechnologies, Inc. (AAVL) to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, has been appointed to serve as Lead Counsel in the consolidated class action captioned In re Avalanche Biotechnologies, Inc., Sec. Litig.,... 
From GlobeNewswire News Releases
16 Biotechnology Stocks to Sell Now
 
Tags NASDAQ:NWBO NASDAQ:ORPN NASDAQ:MEIP
From InvestorPlace
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Avalanche Biotechnologies, Inc. (AAVL) To Contact The Firm
Tags Business & Professional Services
From ACCESSWIRE
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.